We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis

By MedImaging International staff writers
Posted on 21 Dec 2023
Print article
Image: 18F-PFPMD PET/CT imaging of NSCLC and CRC patients (Photo courtesy of SNMMI)
Image: 18F-PFPMD PET/CT imaging of NSCLC and CRC patients (Photo courtesy of SNMMI)

Kirsten rat sarcoma (KRAS) is a commonly mutated oncogene that is found in about 20-70% of cancer cases. Patients with KRAS mutations generally respond poorly to standard therapies. Hence, it is recommended to assess the mutation status in cancer patients to determine the most effective treatment. Presently, screening for KRAS mutation involves a biopsy combined with gene sequencing. However, biopsies can be accompanied by significant complications and have limited use owing to the quality of the tissue sample. This creates an urgent need for accurate yet noninvasive methods for the evaluation of the KRAS mutation status. Now, a study has found a novel PET imaging tracer to safely and effectively detect the common KRAS cancer gene mutation that is an important molecular marker for tumor-targeted therapy. Early identification of this can allow physicians to tailor treatment plans for patients to achieve the best results.

Researchers at Fourth Military Medical University (Xi’an, China) conducted this first-in-human study to develop a KRAS-targeted radiotracer and examine its targeting potential in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The researchers created an oncoprotein-targeted PET tracer, 18F-PFPMD, based on a recently FDA-approved KRASG12C inhibitor. The team conducted both in vitro and in vivo studies to assess the tracer’s targeting specificity and imaging ability. The researchers also carried out further evaluation in healthy volunteers, NSCLC patients, and CRC patients.

The researchers obtained 18F-PFPMD with a high radiochemical yield, radiochemical purity, and stability and proved that it could selectively bind to the KRASG12C protein in preclinical studies. They found the tracer to be safe for humans, with the ability to clear rapidly from the gallbladder and intestines. Among NSCLC and CRC patients, the accumulation of 18F-PFPMD was much higher in tumors with the KRASG12C mutation as compared to those without the mutation.

“This research reveals that 18F-PFPMD is a promising molecular imaging tool of significant clinical relevance,” said Jing Wang, MD, PhD, nuclear medicine physician at Xijing Hospital of Fourth Military Medical University. “Moving forward, the tracer could be useful to screen the KRASG12C mutation status, as well as for patient selection of KRASG12C targeted therapy. Moreover, it could be used for monitoring therapeutic response and drug resistance for cancer patients.”

Related Links:
Fourth Military Medical University

Gold Member
Solid State Kv/Dose Multi-Sensor
Digital Radiography System
DuraDiagnost F30
Ultrasound Software
UltraExtend NX
Portable X-Ray Unit

Print article



view channel
Image: LumiGuide enables doctors to navigate through blood vessels using light instead of X-ray (Photo courtesy of Philips)

3D Human GPS Powered By Light Paves Way for Radiation-Free Minimally-Invasive Surgery

In vascular surgery, doctors frequently employ endovascular surgery techniques using tools such as guidewires and catheters, often accessing through arteries like the femoral artery. This method is known... Read more


view channel
Image: The VR visualization platform provides patients and surgeons with access to real-time 3D medical imaging (Photo courtesy of Avatar Medical)

VR Visualization Platform Creates 3D Patient Avatars from CT and MR Images in Real-Time

Surgeons and patients must currently rely on black and white medical images interpreted by radiologists. This limitation becomes more pronounced in complex surgeries, leading to issues such as patient... Read more


view channel
Image: Intravascular ultrasound provides a more accurate and specific picture of the coronary arteries (Photo courtesy of 123RF)

Intravascular Imaging Significantly Improves Outcomes in Cardiovascular Stenting Procedures

Individuals with coronary artery disease, which involves plaque accumulation in the arteries leading to symptoms like chest pain, shortness of breath, and heart attacks, often undergo a non-surgical procedure... Read more

General/Advanced Imaging

view channel
Image: Routine chest CT holds untapped potential for revealing patients at risk for cardiovascular disease (Photo courtesy of Johns Hopkins)

Routine Chest CT Exams Can Identify Patients at Risk for Cardiovascular Disease

Coronary artery disease (CAD) is the primary cause of death globally. Adults without symptoms but at risk can be screened using EKG-gated coronary artery calcium (CAC) CT scans, which are crucial in assessing... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: The acquisition will expand IBA’s medical imaging quality assurance offering (Photo courtesy of Radcal)

IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering

Ion Beam Applications S.A. (IBA, Louvain-La-Neuve, Belgium), the global leader in particle accelerator technology and a world-leading provider of dosimetry and quality assurance (QA) solutions, has entered... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.